e-learning
resources
Virtual 2020
Pre-Congress Content
Tuberculosis and comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Social determinants and co-morbidities of patients with extensively drug resistant tuberculosis
L. Parolina (Moscov, Russian Federation), O. Otpuschennykova (Moscov, Russian Federation), N. Kazimirova (Moscov, Russian Federation), N. Doktorova (Moscov, Russian Federation)
Source:
Virtual Congress 2020 – Tuberculosis and comorbidities
Session:
Tuberculosis and comorbidities
Session type:
E-poster session
Number:
497
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Parolina (Moscov, Russian Federation), O. Otpuschennykova (Moscov, Russian Federation), N. Kazimirova (Moscov, Russian Federation), N. Doktorova (Moscov, Russian Federation). Social determinants and co-morbidities of patients with extensively drug resistant tuberculosis. 497
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Social problems of drug resistant tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 15s
Year: 2006
A study of prevalence of depression in patients with multi drug resistant tuberculosis
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Source: Eur Respir J 2009; 33: 1085-1094
Year: 2009
Outcome of multidrug resistant tuberculosis (MDR-TB) treatment with possible influencing factors
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Psychiatric issues during the treatment of the patients with multidrug-resistant tuberculosis
Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Year: 2005
Epidemiologic and sociodemographic factors in multidrug resistant tuberculosis patients
Source: Eur Respir J 2001; 18: Suppl. 33, 142s
Year: 2001
Risk factors for treatment failure in multidrug-resistant and extensively drug-resistant tuberculosis in Estonia
Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control
Year: 2008
Risk factors for multi-drug resistant TB in children and adolescents
Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases
Year: 2007
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Factors associated with treatment outcome in 64 HIV negative patients with multidrug resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country.
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Treatment outcomes among childhood extensively drug-resistant tuberculosis patients in Pakistan
Source: ERJ Open Res, 8 (1) 00551-2021; 10.1183/23120541.00551-2021
Year: 2022
Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs
Source: Annual Congress 2010 - Prognosis of tuberculosis
Year: 2010
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens
Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017
Year: 2017
Clinical outcomes of patients with drug-resistant and extensively drug-resistant tuberculosis in Europe
Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET)
Year: 2008
Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome
Source: International Congress 2017 – TB: co-morbidities and outcome
Year: 2017
Risk factors for radiological and functional sequelae in multi-drug resistant tuberculosis
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
Source: Eur Respir J 2016; 48: 938-943
Year: 2016
Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre
Source: Eur Respir J 2003; 22: Suppl. 45, 524s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept